Moderna, Inc. (MRNA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:34AM EDT. Market open.
| Previous close | 145.36 |
| Open | 143.00 |
| Bid | 143.83 x 1200 |
| Ask | 144.97 x 1300 |
| Day's range | 143.20 - 147.90 |
| 52-week range | 115.61 - 497.49 |
| Volume | |
| Avg. volume | 6,068,288 |
| Market cap | 58.713B |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | 4.34 |
| EPS (TTM) | 34.02 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 219.33 |
- Zacks
Moderna (MRNA) Gains As Market Dips: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.
- Zacks
Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
- Motley Fool
Could This Be Moderna's Ticket to Long-Term Success?
Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success?
© 2022 Yahoo. All rights reserved.
